We are live on ! Find out more
EAM

Exome Asset Management Portfolio holdings

AUM $193M
1-Year Est. Return 208.51%
This Fund
S&P 500
This Quarter Est. Return
+11.92%
1 Year Est. Return
+208.51%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$148M
AUM Growth
+$35.6M
Cap. Flow
+$28.1M
Cap. Flow %
18.99%
Top 10 Hldgs %
35.62%
Holding
82
New
30
Increased
14
Reduced
8
Closed
23

Top Buys

Rank Stock Value
1
GPCR icon
Structure Therapeutics
GPCR
+$4.65M
2
ALGN icon
Align Technology
ALGN
+$4.41M
3
GERN icon
Geron
GERN
+$4.12M
4
GILD icon
Gilead Sciences
GILD
+$3.82M
5
SWTX
SpringWorks Therapeutics
SWTX
+$3.76M

Top Sells

Rank Stock Value
1
SRPT icon
Sarepta Therapeutics
SRPT
+$5.2M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$3.84M
3
TVTX icon
Travere Therapeutics
TVTX
+$3.64M
4
ONC
BeOne Medicines Ltd
ONC
+$3.22M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$3.03M

Sector Composition

Rank Sector Weight
1 Healthcare 98.79%
2 Financials 0.18%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INSM icon
26
Insmed
INSM
$22.4B
$2.45M 1.66%
33,600
-23,200
-41% -$1.71M
LEGN icon
27
Legend Biotech
LEGN
$3.65B
$2.29M 1.55%
+47,000
New +$2.5M
MRSN
28
DELISTED
Mersana Therapeutics
MRSN
$2.23M 1.51%
+47,143
New +$2.08M
ETNB
29
DELISTED
89bio
ETNB
$2.22M 1.5%
+300,600
New +$2.53M
AKRO
30
DELISTED
Akero Therapeutics
AKRO
$2.21M 1.5%
+77,100
New +$2.01M
CNTA
31
DELISTED
Centessa Pharmaceuticals
CNTA
$2.21M 1.49%
138,152
-136,748
-50% -$1.68M
STOK icon
32
Stoke Therapeutics
STOK
$1.84B
$2.17M 1.47%
+176,600
New +$2.5M
AMGN icon
33
Amgen
AMGN
$209B
$2.16M 1.46%
6,700
-5,100
-43% -$1.67M
GH icon
34
Guardant Health
GH
$19.1B
$2.06M 1.39%
89,800
+10,800
+14% +$306K
NUVL
35
DELISTED
Nuvalent
NUVL
$2.04M 1.38%
+19,945
New +$1.65M
RVNC
36
DELISTED
Revance Therapeutics, Inc.
RVNC
$1.8M 1.22%
+347,600
New +$1.73M
KURA icon
37
Kura Oncology
KURA
$793M
$1.76M 1.19%
90,305
-41,437
-31% -$840K
RZLT icon
38
Rezolute
RZLT
$453M
$1.71M 1.15%
352,056
+69,656
+25% +$320K
PLRX icon
39
Pliant Therapeutics
PLRX
$65M
$1.68M 1.13%
149,600
+25,600
+21% +$320K
EWTX icon
40
Edgewise Therapeutics
EWTX
$4.28B
$1.6M 1.08%
+59,900
New +$1.19M
STAA icon
41
STAAR Surgical
STAA
$1.19B
$1.52M 1.02%
+40,800
New +$1.52M
TARS icon
42
Tarsus Pharmaceuticals
TARS
$2.55B
$1.5M 1.01%
+45,600
New +$1.28M
BCRX icon
43
BioCryst Pharmaceuticals
BCRX
$2.42B
$1.49M 1.01%
+196,500
New +$1.49M
SRRK icon
44
Scholar Rock
SRRK
$5.88B
$1.12M 0.75%
+133,039
New +$1.17M
TECX
45
Tectonic Therapeutic
TECX
$536M
$1.1M 0.74%
36,344
+3,955
+12% +$72.3K
ALVO icon
46
Alvotech
ALVO
$1.19B
$1.07M 0.72%
90,100
-8,900
-9% -$103K
QTRX icon
47
Quanterix
QTRX
$159M
$953K 0.64%
73,501
+13,851
+23% +$185K
ESTA icon
48
Establishment Labs
ESTA
$2.71B
$939K 0.63%
21,700
– –
ACRV icon
49
Acrivon Therapeutics
ACRV
$61.2M
$817K 0.55%
+116,757
New +$920K
LXEO icon
50
Lexeo Therapeutics
LXEO
$338M
$797K 0.54%
+88,148
New +$1.05M
1
2
3 4

Similar funds

WWC
Waypoint Wealth Counsel Atlanta, Georgia $193M AUM 30.17% 1-Year Est. Return
JHA
Jackson Hill Advisors Houston, Texas $193M AUM 4.94% 1-Year Est. Return
TDWM
Topel & Distasi Wealth Management Berkeley, California $193M AUM 12.07% 1-Year Est. Return
DF
Downshift Financial Boulder, Colorado $193M AUM
SCM
Sandler Capital Management New York $193M AUM 77.14% 1-Year Est. Return
PA
Promethium Advisors Bethesda, Maryland $193M AUM 23.69% 1-Year Est. Return
SCPM
Sea Cliff Partners Management San Francisco, California $194M AUM 8.22% 1-Year Est. Return
EWM
Evergreen Wealth Management Williamston, Michigan $194M AUM 13.93% 1-Year Est. Return

Exome Asset Management's Q3 2024 Portfolio in Review

As of Q3 2024, Exome Asset Management held 82 positions worth $148M, up 32% from $112M the previous quarter. Its ten largest holdings account for 36% of the portfolio.

Exome Asset Management deployed $28.1M of net new capital in Q3 2024, opening 30 new positions and adding to 14 existing holdings. Its largest new stake was Structure Therapeutics: 120,165 shares worth $5.27M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was BeOne Medicines Ltd, an estimated $3.22M trimmed.

  • Exome Asset Management's largest Q3 2024 buy was Structure Therapeutics: 120,165 shares worth $5.27M.
  • Exome Asset Management added most to BridgeBio Pharma in Q3 2024, an estimated $3.47M increase.
  • Exome Asset Management's biggest Q3 2024 reduction was BeOne Medicines Ltd, cutting an estimated $3.22M.
  • Exome Asset Management fully exited Sarepta Therapeutics in Q3 2024, selling an estimated $5.2M.
  • Exome Asset Management's ten largest holdings make up 36% of its $148M portfolio in Q3 2024.
  • Exome Asset Management opened 30 new positions and closed 23 in Q3 2024.
  • Exome Asset Management's portfolio value rose 32% quarter-over-quarter to $148M.

Based on Exome Asset Management's 13F filing for Q3 2024, filed 14 Nov 2024.